Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

The Food and Drug Administration (FDA) accepted Pfizer’s application for an RSV vaccine for older adults, and is expected to make an approval decision by the spring. Pfizer in a statement on Wednesday ...

Pfizer disclosed a patient death in a marstacimab hemophilia study, triggering a safety review and reassessment of surgical ...

Please provide your email address to receive an email when new articles are posted on . The FDA has accepted for priority review a supplemental biologics license application for Pfizer’s 20-valent ...

Pfizer is rushing to get its respiratory syncytial virus (RSV) vaccine out the door and into arms. A priority review from the FDA will certainly help. The pharma giant announced Wednesday that U.S.

Thirteen essential drugs made at Pfizer’s Rocky Mount, N.C., facility — which was recently damaged by a tornado — have a vulnerability score higher than 90 percent, according to a July 26 report from ...

Pfizer (NYSE:PFE) announced Tuesday that the FDA accepted its Biologics License Application (BLA) for its respiratory syncytial virus (RSV) vaccine candidate PF-06928316 for priority review targeting ...

As Moderna’s COVID vaccine patent lawsuits wind their way through courts around the globe, Pfizer and BioNTech contend their rival is trying to monopolize the entire mRNA field. In the latest chapter ...

In a change of pace from the recent COVID-related business struggles for Pfizer, the drugmaker has picked up a valuable reward from the FDA in the form of a priority review voucher (PRV). The agency ...

NEW YORK (Reuters) - U.S. health regulators have not yet completed their review of a more protective form of Pfizer Inc's big-selling Prevnar vaccine that fights pneumonia and meningitis, the ...

Pfizer has agreed to acquire weight-loss drugmaker Metsera in a transaction that could exceed $10 billion. Under the terms of the cash deal, Pfizer will pay $65.60 a share upfront, along with a ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted priority review to a biologics license application for Pfizer’s respiratory syncytial virus ...